These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 24012857

  • 1. The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay.
    Yang J, Sa M, Huang M, Yang J, Xiang Z, Liu B, Tang A.
    Clin Biochem; 2013 Nov; 46(16-17):1705-8. PubMed ID: 24012857
    [Abstract] [Full Text] [Related]

  • 2. Measurement of HE4 and CA125 and establishment of reference intervals for the ROMA index in the sera of pregnant women.
    Lu J, Zheng Z, Zhang Q, Li G, Li F, Le Z, Huang J, Xie X, Zhang J.
    J Clin Lab Anal; 2018 Jun; 32(5):e22368. PubMed ID: 29194801
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A, Perumal V, Ammalli P, Suryan V, Bansal SK.
    Sci Rep; 2021 Aug 27; 11(1):17308. PubMed ID: 34453074
    [Abstract] [Full Text] [Related]

  • 4. Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women.
    Yu S, Lee JK, Kim JH, Park H, Lee MY, Ryu S, Kwon MJ, Woo HY.
    Gynecol Oncol; 2016 Oct 27; 143(1):128-134. PubMed ID: 27426308
    [Abstract] [Full Text] [Related]

  • 5. The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer.
    Zhang Q, Wang CR, Yu JP, Ma Q, Xu WW.
    J Clin Lab Anal; 2016 Sep 27; 30(5):709-18. PubMed ID: 26990679
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Proofs for implementation of higher HE4 and ROMA index cut-off values in ovarian cancer preoperative stratification.
    Špacir Prskalo Z, Bulić P, Langer S, Gaće M, Puljiz M, Danolić D, Alvir I, Mamić I, Šušnjar L, Mayer L.
    J Obstet Gynaecol; 2019 Feb 27; 39(2):195-201. PubMed ID: 30207507
    [Abstract] [Full Text] [Related]

  • 8. A new strategy for calculating the risk of ovarian malignancy algorithm (ROMA).
    Jeong TD, Cho EJ, Ko DH, Lee W, Chun S, Kwon HJ, Hong KS, Kim YM, Min WK.
    Clin Chem Lab Med; 2017 Jul 26; 55(8):1209-1214. PubMed ID: 28107166
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C, Leon AE, Fabricio ASC, Taborelli M, Polesel J, Del Pup L, Steffan A, Cervo S, Ravaggi A, Zanotti L, Bandiera E, Odicino FE, Scattolo N, Squarcina E, Papadakis C, Maggino T, Gion M.
    Gynecol Oncol; 2016 May 26; 141(2):303-311. PubMed ID: 26801941
    [Abstract] [Full Text] [Related]

  • 11. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M, Stieber P, Hertlein L, Kirschenhofer A, Fürst S, Mayr D, Nagel D, Hofmann K, Krocker K, Burges A.
    Clin Chem Lab Med; 2011 Sep 16; 49(12):2081-8. PubMed ID: 21923475
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Ovarian tumor markers of presumed benign ovarian tumors].
    Lahlou N, Brun JL.
    J Gynecol Obstet Biol Reprod (Paris); 2013 Dec 16; 42(8):752-9. PubMed ID: 24210243
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population.
    Richards A, Herbst U, Manalang J, Pather S, Saidi S, Tejada-Berges T, Tan K, Williams P, Carter J.
    Aust N Z J Obstet Gynaecol; 2015 Oct 16; 55(5):493-7. PubMed ID: 26172511
    [Abstract] [Full Text] [Related]

  • 16. Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125.
    Chudecka-Głaz A, Cymbaluk-Płoska A, Luterek-Puszyńska K, Menkiszak J.
    Oncol Lett; 2016 Nov 16; 12(5):3101-3114. PubMed ID: 27899969
    [Abstract] [Full Text] [Related]

  • 17. HE4 and ROMA index in Czech postmenopausal women.
    Novotny Z, Presl J, Kucera R, Topolcan O, Vrzalova J, Fuchsova R, Betincova L, Rokyta Z.
    Anticancer Res; 2012 Sep 16; 32(9):4137-40. PubMed ID: 22993374
    [Abstract] [Full Text] [Related]

  • 18. The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients.
    Ikeda Y, Hasegawa K, Kurosaki A, Miyara A, Hanaoka T, Shintani D, Imai Y, Nishikawa T, Oda K, Fujiwara K.
    Oncol Res Treat; 2015 Sep 16; 38(6):276-81. PubMed ID: 26045023
    [Abstract] [Full Text] [Related]

  • 19. Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status?
    Chudecka-Głaz A, Cymbaluk-Płoska A, Jastrzębska J, Menkiszak J.
    Tumour Biol; 2016 Jul 16; 37(7):8879-87. PubMed ID: 26753953
    [Abstract] [Full Text] [Related]

  • 20. Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.
    Urban N, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, Paley P, Drescher CW.
    Cancer Epidemiol Biomarkers Prev; 2012 Nov 16; 21(11):2087-94. PubMed ID: 22962406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.